

## **Pitfalls in the Diagnosis and Management of Tuberculosis**

Amea Patrawalla, MD, MPH  
Assistant Professor  
Rutgers – NJ Medical School


November 20<sup>th</sup>, 2013

Rutgers, The State University of New Jersey


### **Avoiding Pitfalls in Recognizing TB Disease**

- **Maintain a high index of suspicion**
  - ‘Usual’ risk groups
  - Diabetes, Autoimmune disease, Transplant, CKD, Malnutrition
  - AFB smear negative ≠ no TB
- **Settings where diagnostic delays commonly occur**
  - HIV, Extrapulmonary TB, smear negative disease,
- **Request a thorough microbiologic work-up in unusual cases**
  - May require multiple or repeated diagnostic procedures
- **Consult with local and regional public health authorities and TB experts**

### Diagnosis of TB



### Drug – O - Gram



### Case 1

- 29 year old Indian man who presents with right leg pain for 4 years
- Noted right ankle swelling about 1 year ago, and presented to Orthopedic clinic
- No cough, fevers, chills, night sweats or weight loss


### Prior History

- 2006
  - Developed cough, fever and weight loss while visiting Denmark. Was treated for pneumonia without improvement
  - Tuberculin skin test positive
  - Returned to India with persistent symptoms and was started on a combination pill including INH, RIF and EMB for presumed pulmonary TB. Took all medications as directed for 6 months with clinical improvement.
- 2007 – Moved to US
- 2011 – Developed right ankle swelling

September 2011



October 2011




January 2012

- Underwent partial excision of fibula and deep biopsy of soft tissue and bone
- Findings – soft tissue mass and lateral malleolus erosion
- Frozen and final path – necrotizing granulomas

Microbiology

- Tissue and bone specimens – AFB smear neg
- Re-review of path specimen – solitary AFB
- MTB PCR + on tissue
- Tissue and bone specimens, MTB culture +




### Extrapulmonary TB

- 21% of all TB cases in US
- Overall rates of TB declining, proportion of EPTB increasing
- Associated with women, foreign-birth, nonwhite race, immune compromise
- Not associated with MDR, incarceration, alcoholism, homelessness
- Meningeal and lymph node TB seen frequently in children
- GU and bone/joint in older adults
- Meningeal and pleural more commonly seen in US born


Peto, CID, 2009  
Fiske, BMC ID, 2010

### Trends in EPTB and PTB; 1993-2006



Peto, CID, 2009

Extrapulmonary tuberculosis sites of disease, United States, 1993–2006 (N=47,293)



Peto, CID, 2009

Table 2 Anatomical site of musculoskeletal TB

| Anatomical site | Patients (n) | Patients (%) |
|-----------------|--------------|--------------|
| Spine           | 29           | 47.6         |
| Cervical        | 2            | 3.2          |
| Thoracic        | 8            | 13.2         |
| Thoracic/lumbar | 4            | 6.6          |
| Lumbar          | 10           | 16.4         |
| Not classified  | 5            | 8.2          |
| Humerus/elbow   | 6            | 9.8          |
| Knee            | 5            | 8.2          |
| Chest wall      | 5            | 8.2          |
| Hip/femur       | 4            | 6.6          |
| Pelvis/SIJ      | 4            | 6.6          |
| Wrist           | 3            | 4.9          |
| Fingers         | 2            | 3.4          |
| Ankle           | 1            | 1.6          |

Talbot, Ann R Coll Surg Engl 2007

## EPTB Diagnosis

- Tends to be paucibacillary, and more difficult to detect microbiologically
- May require invasive/repeated procedures
  - Involves various sub-specialties
- Rapid Tests
  - Nucleic Acid Amplification Tests
  - GeneXpert MTB/RIF

Laraque, CID, 2009  
 Hillemann JCM, 2011  
 Tortoli, ERJ, 2012

## EPTB Treatment

**TABLE 13. Evidence-based\* guidelines for the treatment of extrapulmonary tuberculosis and adjunctive use of corticosteroids†**

| Site                                  | Length of therapy (mo) | Rating (duration) | Corticosteroids‡     | Rating (corticosteroids) |
|---------------------------------------|------------------------|-------------------|----------------------|--------------------------|
| Lymph node                            | 6                      | A1                | Not recommended      | DIII                     |
| Bone and joint                        | 6–9                    | A1                | Not recommended      | DIII                     |
| Pleural disease                       | 6                      | AII               | Not recommended      | DI                       |
| Pericarditis                          | 6                      | AII               | Strongly recommended | A1                       |
| CNS tuberculosis including meningitis | 9–12                   | BII               | Strongly recommended | A1                       |
| Disseminated disease                  | 6                      | AII               | Not recommended      | DIII                     |
| Genitourinary                         | 6                      | AII               | Not recommended      | DIII                     |
| Peritoneal                            | 6                      | AII               | Not recommended      | DIII                     |

\*For rating system, see Table 1.

†Duration of therapy for extrapulmonary tuberculosis caused by drug-resistant organisms is not known.

‡Corticosteroid preparations vary among studies. See Section 8.3 for specific recommendations.

ATS/IDSA/CDC 2003

### Challenges in EPTB

- Fewer TB cases has likely led to lowered suspicion for TB
- Public health focus is primarily on PTB
- Differing risk factors
- Diagnosis often more difficult and delayed
- Treatment efficacy and culture conversion can be difficult to detect
- Multidisciplinary approach often involving surgery, pathology, radiology etc.

### Case 2

- 29 y.o. physician from Pakistan with dry cough x 2 months
- No fever, night sweats or weight loss
- TST negative 6 months previously




### Case 2

- Induced sputum – AFB smear negative
- Quantiferon Gold positive
- Started on multidrug therapy
- Cultures MTB positive 4 weeks later

## Smear-Negative TB

- Sputum smear microscopy sensitivity ~ 50%
  - Lower in HIV and children
- Leads to diagnostic and treatment delays
- Increasingly common, especially in high HIV settings
  - 35 – 40% of US cases
- Smear negative TB accounts for 10-20% of TB transmission
- Leads to one-quarter the number of cases as smear positive index cases

Shah, IJTLD, 2012  
Tostmann, CID, 2008



## Smear-Negative TB

- Is common and transmissible
  - Infection control measures are necessary
- Often entails treatment delays
- Contact tracing is essential, but is often delayed
- Rapid diagnostic tests are moderately sensitive and may help mitigate above
- Treatment similar to smear positive TB
- Empiric therapy may be needed

### Case 3

- 45 y.o. woman currently incarcerated with history of injection drug use.
- Complains of cough, fevers, sweats and weight loss for 2 months.



- No old CXR to compare with


## Case 3

- AFB smear negative
- Started on antitubercular therapy
- Cultures remained negative with minimal improvement in CXR, but resolution of symptoms

## Culture Negative Pulmonary Tuberculosis

- Clinical and radiologic picture of active TB
- Cultures remain negative
  - Paucibacillary
  - Incorrect specimen processing
  - Temporal variation in bacteria shedding
- Perform at least 3 quality sputum exams
- Consider other diagnostics such as bronchoscopy
- Up to 15-20% of reported TB cases in US

## Culture negative TB



ATS/IDSA/CDC 2003

## Culture negative TB

- 4 month regimen of isoniazid and rifampin has been shown to have a 1.2% relapse rate
- GeneXpert MTB/RIF may have some utility


Dutt, 1989  
Marlowe, 2011  
Zeka, 2011

## Atypical Radiographic Presentations

- Lower lobe infiltrates
- Predominant adenopathy
- Miliary or disseminated
- Pleural effusion
- Mass-like opacities
- Pneumothorax


} More common  
in children with  
'primary' TB

## "Classic" Cavitory Tuberculosis



- 31 y.o. man from Ecuador with cough, night sweats, fevers and weight loss

## Non-cavitary Tuberculosis




- 29 y.o. physician from Pakistan with dry cough for 2 months

## Disseminated TB + HIV



- 45 y.o. woman with HIV with cough and fever for 1 week.
  - Treated for LLL pneumonia & parapneumonic effusion without improvement
  - QFT – G negative
  - AFB smears from sputum negative
- Sputum, pleural fluid, blood cultures ultimately grew MTB



### Miliary TB

59 y.o. woman with dermatomyositis, on corticosteroids with shoulder pain and ulcerated tongue mass

### Pneumothorax



### Take Home Points

- TB disease can present in a myriad of ways
- Keep a high index of suspicion especially in certain risk groups
- Utilize infection control measures appropriately
- Become familiar with rapid tests offered in your region and recognize their limitations
- Collaborate closely with primary care, specialists, microbiologist, public health authorities and experts



## Diagnosis of TB Meningitis A Case From New Hampshire

Elizabeth A. Talbot, MD

Deputy State Epidemiologist, NH DHHS  
Associate Professor, ID Section,  
Dartmouth Medical School

### Routine Report of Suspect Bacterial Meningitis



- Feb 27: suspect bacterial meningitis reported to NH DHHS
- 19yo male from China with F, HA, weakness, photophobia, N/V and suggestive CSF
  - Student at UNH
- Question regarding *N. meningitidis* prophylaxis for girlfriend and at school

## History Prior to Suspect Bacterial Meningitis



- Dec 13-17 (2m PTA) hospitalized for RLL pneumonia and effusion
  - Thoracentesis done (neg AFB smear)
  - HIV test negative
  - Received 14 days of levaquin: cough improved
- Dec 2012-Jan 2013 (1m PTA) hospitalized in China for pneumonia
  - Told “not TB” (TST neg)
  - Received 10 days of unknown antibiotic: cough improved

## HPI (This Episode)



- Feb 14 (10d PTA): Nonspecific symptoms
- Feb 18 and 20 ED “not feeling well”
  - Azithromycin given
- Feb 24 presented to ED (3rd time) with HA, F, weakness and photophobia
  - Admitted
  - HCT: no acute intracranial abnormality
  - Feb 28 LP glu 25, pro 169, WBC 370 with 70% PMNs. No bacterial growth; AFB not done
- Started on IV cipro and "improving"

## Routine Report of Suspect Bacterial Meningitis



- Feb 27: suspected bacterial meningitis reported to [redacted]
- 19yo male from China with F, HA, weakness, photophobia, N/V and suggestive CSF
  - Student at UNH
- Question regarding *N. meningitidis* prophylaxis for girlfriend and at school

## History Prior to Suspect Bacterial Meningitis



- Dec 13-17 (2m PTA) hospitalized pneumonia and effusion
  - Thoracentesis done (neg AFB smear)
  - HIV test negative
  - Received 14 days of levaquin: cough improved
- Dec 2012-Jan 2013 (1m PTA) hospitalized in China for pneumonia
  - Told “not TB” (TST neg)
  - Received 10 days of unknown antibiotic: cough improved


## HPI (This Episode)




- Feb 14 (10d PTA): Nonspecific symptoms
- Feb 18 and 20 ED “not feeling well”
  - Azithromycin given
- Feb 24 presented to ED (3rd time) with HA, F, weakness and photophobia
  - Admitted 
  - HCT: no acute in  abnormality
  - Feb 28 LP glu 25, pro 169, WBC 370 with 70% PMNs. No bacterial growth; AFB not done
- Started on IV cipro and "improving"

## “Could This be TB Meningitis (TBM)?”

- Navigated first CSF to probe and AFB
- Patient became confused, weak: seizures
  - Normal sodium throughout
  - Transferred to ICU
- Mar 4 second CSF collected: AFB sm pos
  - Isolate sent to CDC for sensitivity testing
- Mar 6 first CSF positive Gen Probe for MTBC; AFB sm/cx negative
  - Started RIPE, steroid, antiepileptic 17d after presentation  
11d after admission
- Mar 16: transferred to MGH for worsening



*MRI Axial T1 post contrast images show intensely enhancing basal exudates with multilocularity on left side of mid brain which is very typical of tuberculosis.*



*An associated diffuse lepto meningeal enhancement and an associated hydrocephalus.*

## Complicated Course



- Mar 19 (d13 tx) neuro status worse
  - Added moxi + amikacin to RIPE
- Third LP AFB sm pos
- Mar 21 second CSF isolate pansensitive
- Mar 29 (d23 tx) CN deficits result in double vision and balance problems
- Aug 1 family took him back to China
- Eventually returned to normal neurologic function

## NH's Clinical Summary



- Two unexplained pneumonias in otherwise healthy young adult from China
- Presented with nonspecific (but perceived urgent symptoms) over 10 days
- Presentation and CSF suggested TBM
- RIPE started 17 days after presentation
  - Aminoglycoside and fluoroquinolone added two weeks later when deteriorated
- TBM diagnosis confirmed by probe, smear, culture



## TB Meningitis Diagnosis




## TBM Pathogenesis



TB bacteremia occurs in primary or reactivation disease and establishes subependymal tubercles (Rich foci) which rupture into subarachnoid space → meningitis



- At base of brain
  - Dense gelatinous exudate develops
  - Surrounds arteries and CNs
- Results in
  - Hydrocephalus
  - Vasculitis → infarction, hemiplegia, quadriplegia



neuropathology.neucom.edu

Tuberculous Meningitis. Donald and Shoerman, NEJM. 351:17. 10/21/2004

## TBM Outcomes

Donald, PR and Schoerman, JF. Tuberculous Meningitis. NEJM, 351:17. 2004.

- **3 Stages:**
  - **Lucid: insidious HAF; 2-3 wks**
    - 19% mortality
  - **Meningitic phase: meningismus, N/V, CN palsies**
    - 69% mortality
  - **Paralytic phase: stupor, coma, seizure, pareses**
- **1/3 - 1/2 patients complete neuro recovery**
- **1/3 have residual severe neurologic deficits such as hemiparesis, blindness, seizure disorder**

## Prognosis Study

J Microbiol Immunol Infect 2002; 35(4): 215

- **University Hosp in Taiwan**
- **41 adults in retrospective cohort**
  - Age 16-80 (med 41)
  - 41% with immunocompromise
- **Mortality 10%; morbidity 56%**
  - AFB+ CSF worse prognosis
  - 19 patients got worse during therapy



## Another Prognosis Study

UK Misra, *et al.* Prognosis of tuberculous meningitis: a multivariate analysis. *J Neurol Sci* 1996;137:57-61

- Among 49 adults/children with TBM, most significant predictors of outcome
  - Age
  - Stage of disease
  - Focal weakness
  - Cranial nerve palsy
  - Hydrocephalus
  - Delayed treatment



## Diagnosis: CSF Examination



- Usually lymphocytic pleocytosis, elevated protein, depressed glucose
- AFB stain: sensitivity 10-60%
  - Median time to see 10 minutes
- MTB culture: sens 25-75% 2-6 weeks
  - Better with increased volume, up to 6 mL
- GeneXpert MTB/RIF: automated realtime PCR
- Adenosine deaminase (ADA) level

## Studies of Gene Xpert MTB/RIF on Extrapulmonary Specimens

- Pre-2011 metanalysis found sens 80% [95% CI 75-85]\*\*
- Systematic review of 18 studies of 10,224 pulmonary and EP patients
  - Sens med 77% (range 25-97%)
  - Specificity 98% [98-99]\*
  - Variation between populations, selection, type of EPTB, sample processing, ref standard . . .



\*Lawn et al. Lancet Infect 13: Apr 2013; \*\*Chang et al. J infect 2012 64: 580-8

## Selected\* (Mixed) EPTB Studies


\*>100 patients, non-urine, control group

| Author     | # Pts | Sample(s)   | Sens | Spec |
|------------|-------|---|------|------|
| Causse     | 340   | Tissue, gastric aspirate, pleural fluid, pus              | 95   | 100  |
| Hillermann | 521   | Tissue, gastric aspirate                                  | 77   | 98   |
| Moure      | 149   | SMEAR NEG pleural fluid, lymph node, pus, tissue          | 58   | 100  |
| Vadwai     | 533   | Tissue, pus, body fluids                                  | 81   | 100  |
| Zeka       | 176   | Pleural fluid, lymph node, CSF, pericardial fluid, tissue | 54   | 100  |
| Tortoli    | 1474  | Mixed   | 81   | 100  |

Xpert as a “Rule-in Test”?

# Adenosine Deaminase

## ADA Reflects Immune Cell Activity



Having phagocytosed *M. tuberculosis*, macrophages secrete a panel of cytokines (e.g. IL-12 and IL-18) which interact with various cell populations including natural killer (NK) cells and CD4(+) cells. This leads to the activation of these cells and the stimulation of interferon gamma (IFN- $\gamma$ ) release. IFN- $\gamma$  induces macrophage bactericidal mechanisms. Activated macrophages release adenosine deaminase 2 (ADA2), whereas ADA1 is released from macrophages and lymphocytes as well.

# Metanalyses of ADA

Krenke R et al. Use of Pleural Fluid Levels of ADA. Current Opinion in Pulm Med 2010; 16

- Pleural effusion, ascites, CSF
- Most show sens/spec 90/<90
- (Our patient did not have it done)

Table 2 Results of the selected studies comparing the diagnostic performance of pleural fluid ADA and IFN- $\gamma$  in patients w

| Author                       | No. of patients studied | Cause of pleural effusion |               |                 |           | ADA             |                 |
|------------------------------|-------------------------|---------------------------|---------------|-----------------|-----------|-----------------|-----------------|
|                              |                         | Tuberculous (n)           | Malignant (n) | PPE/empyema (n) | Other (n) | Sensitivity (%) | Specificity (%) |
| Sharma and Banga [65]        | 52                      | 35                        | 17            | 0               | 0         | 91.4            | 100             |
| Gao and Tian [55]            | 190                     | 141                       | 49            | 0               | 0         | 82.3            | 87.8            |
| Morimoto et al. [66]         | 65                      | 19                        | 33            | 4               | 9         | 78.9            | 97.8            |
| Xue et al. [67]              | 87                      | 45                        | 42            | 0               | 0         | 80.2            | 87.6            |
| Daniil et al. [68]           | 72                      | 12                        | 45            | 15              | 0         | na              | na              |
| Krenke et al. [5]            | 94                      | 28                        | 35            | 20              | 11        | 100             | 93.9            |
| Ariga et al. [69]            | 75                      | 28                        | 26            | 12              | 9         | 81.5            | 91.5            |
| Valdés et al. [57*]          | 96                      | 39                        | 42            | 15              | 0         | 97.4            | 93.0            |
| Dheda et al. [29,51**]       | 67                      | 48                        | 13            | 3               | 3         | 96.0            | 69.0            |
| Total (number/mean $\pm$ SD) | 798                     | 395                       | 302           | 69              | 32        | 88.5 $\pm$ 8.7  | 90.1 $\pm$ 9.6  |

AUC, area under curve; na, data not available; PPE, parapneumonic effusion.

## Diagnosis: Imaging

- CXR shows
  - Primary, miliary or old TB
  - Normal
- CT/MRI demonstrates
  - Hydrocephalus, basilar exudates and inflammation
  - Tuberculomas
  - Infarctions



## Thwaites Score

Thwaites GE, Chau TT, Stepniewska K, Phu NH, Chuong LV, Sinh DX, et al.  
 Diagnosis of adult TBM by use of clin and lab features. Lancet  
 2002;360(9342):1287-1292

- 5 variables predictive in Vietnam adults
  - Max score 13
  - $\leq 4$  TBM
  - $> 4$  bacterial
- Sens/spec 97/91%
- NH case score
  - $0+0-5+0+0=-5$

Weighted diagnostic index scores for dichotomized clinical variables used for admission diagnostic rule


|                                | Weighted diagnostic index score |
|--------------------------------|---------------------------------|
| Age (years)                    |                                 |
| $\geq 36$                      | 2                               |
| $< 36$                         | 0                               |
| Blood WCC ( $10^3/\text{mL}$ ) |                                 |
| $\geq 15,000$                  | 4                               |
| $< 15,000$                     | 0                               |
| Duration of illness (days)     |                                 |
| $\geq 6$                       | -5                              |
| $< 6$                          | 0                               |
| CSF WCC ( $10^3/\text{mL}$ )   |                                 |
| $\geq 900$                     | 3                               |
| $< 900$                        | 0                               |
| CSF % neutrophils              |                                 |
| $\geq 75$                      | 4                               |
| $< 75$                         | 0                               |

WCC, white cell count; CSF, cerebrospinal fluid.

## Thwaites Team Validation

Torok et al. Validation of diagnostic algorithm for adult TBM.  
Am J Trop Med Hyg 2007; 77(3):555-9.


- 205 inpatients in same hospital in Vietnam
- TBM sens 99%



## Algorithm Extensions

Dendane et al. Simple diagnostic aid for TBM in adults in Morocco by use of clinical and lab features. Int ID J 2013; 17(6):e461-5

- 508 adults admitted to ICU in Morocco who satisfied criteria for TBM ( $n = 274$ ) or bacterial meningitis ( $n = 234$ )
- Retrospective MVA and classification and regression tree (CART) without CNS radiology available
- For score  $>7$ 
  - Sens 87% and 88%
  - Spec 96% and 95%




# Lancet Consensus Scoring System

Marais S, Thwaites G, Schoeman JF, Torok ME, Misra UK, Prasad K, et al. TBM: a uniform case def for use in clinical research. Lancet ID 2010 Nov;10(11):803-812.

- 20 parameters in 4 categories
  - Clinical
  - CSF
  - CNS imaging
  - Evidence of TB elsewhere
- Max score 20

|   | Diagnostic score |
|---|------------------|
| <b>Clinical criteria (Maximum category score=6)</b>   |                  |
| Symptom duration of more than 5 days  | 4                |
| Systemic symptoms suggestive of tuberculosis (one or more of the following): weight loss (or poor weight gain in children), night sweats, or persistent cough for more than 2 weeks | 2                |
| History of recent (within past year) close contact with an individual with pulmonary tuberculosis or a positive TST or IGRA (only in children <10 years of age)                     | 2                |
| Focal neurological deficit (excluding cranial nerve palsies)  | 1                |
| Cranial nerve palsy   | 1                |
| Altered consciousness   | 1                |
| <b>CSF criteria (Maximum category score=4)</b>  |                  |
| Clear appearance  | 1                |
| Cells 10-500 per µl   | 1                |
| Lymphocytic predominance (>50%)   | 1                |
| Protein concentration greater than 1 g/L  | 1                |
| CSF to plasma glucose ratio of less than 50% or an absolute CSF glucose concentration less than 2.2mmol/L   | 1                |
| <b>Cerebral imaging criteria (Maximum category score=6)</b>   |                  |
| Hydrocephalus   | 1                |
| Basal meningeal enhancement   | 2                |
| Tuberculoma   | 2                |
| Infarct   | 1                |
| Pre-contrast basal hyperdensity   | 2                |
| <b>Evidence of tuberculosis elsewhere (Maximum category score=4)</b>  |                  |
| Chest radiograph suggestive of active tuberculosis: signs of tuberculosis-2, miliary tuberculosis-4   | 2/4              |
| CT/MRI/ultrasound evidence for tuberculosis outside the CNS   | 2                |
| AFB identified or Mycobacterium tuberculosis cultured from another source—ie, sputum, lymph node, gastric washing, urine, blood culture   | 4                |
| Positive commercial M tuberculosis NAAT from extra-neural specimen  | 4                |
| Exclusion of alternative diagnoses  |                  |



**Definite TBM:** micro id or evidence from commercial NAAT of CNS  
**Probable TBM:** imaging available,  $\geq 12$ ; imaging not available,  $\geq 10$   
**Possible TBM:** imaging available, 6–11, imaging not available, 6–9

**Our case: 15**

Marais et al. Lancet Infect Dis 2010;10: 803–12

## Summary

- Diagnosing TBM requires high clinical suspicion
  - Poor prognosis linked to delays
- Health departments retain TB diagnostic vigilance and can facilitate
- Clinical scores/algorithms are available
- Rely on presentation, risk factors, imaging, routine CSF exams +/- ADA
  - GeneXpert may be useful “rule in test”

# Pitfalls in Dx TB: Diagnosis Delayed

11/20/2013

Marie Turner, MD  
Katherine McGowan, MD

## 25 year old male


- 25 yo American born Cambodian male
- Father had Tuberculosis 1 year previously (parents had lived in Vietnam and traveled back and forth frequently)
- Contact investigation by public health:
  - ◆ Patient not screened as he was unavailable (going to college and had a catering job on the side)
  - ◆ All other family members were TST negative



## 25 year old male



- ♦ 1/2013: experienced flu-like symptoms with a dry cough
- ♦ Cough attributed to smoking cessation
- ♦ No weight loss but by 4/2013: developed fevers, drenching night sweats, continued cough
- ♦ 5/2013: noted headache and sister felt his head “looked funny” and convinced him to go for assessment. Went to ED


## ED

- ♦ Seen in ED
- ♦ Scalp mass palpated
- ♦ Physician orders plain films


















## RC: TB treatment

- ♦ Patient started on INH/Rifampin/PZA/EMB plus Moxifloxacin, Amikacin and Cycloserine
- ♦ Sputum grew pansensitive TB

## Treatment Course

- Patient received 2 months of IV Capreomycin with resolution of the cold abscess of the head
- Thoracic and cervical pain much improved
- Headache continues
- Cycloserine d/c'd at 5 months
- Headache resolves



## Visit 11/8/2013

- ♦ Spirits markedly improved on Zoloft
- ♦ Mass on head gone
- ♦ No side effects from meds
- ♦ Currently on boosted Isoniazid, boosted Rifampin, Ethambutol and Pyrazinamide (off Cycloserine, Capreomycin and Moxifloxacin)

## 21 year old female

- ♦ Born in China
- ♦ Came to US in 2009 to attend U Mass
- ♦ Positive TST 16 mm
- ♦ CXR negative
- ♦ Declined LTBI therapy
- ♦ Well until 12/12

## 12/7/12 symptoms

- Developed cough
- Went to student health
- No chest x-ray
- Treated with azythromycin x two
- Perhaps slight improvement
- Leaves on Christmas break for China  
12/25/12


## While in China

- Parents note coughing
- Brought to local hospital
- CXR and CT accomplished
- Both abnormal
- AFB smear negative
- Told OK to return to US
- Dx pneumonia, not TB


## CXR in China




## CT China



## CT continued






## CT China







## Back in Boston

- Continues to cough over the next 5 months
- Multiple visits with midlevel HCP at PCP office who does multiple CXRs as well as CTs
- Multiple courses of antibiotics including fluoroquinolones, Augmentin, azithromycin as well as inhaled corticosteroids













## Cough/Cough



- By June, patient is no better
- Patient requests consult with pulmonary physician
- Told this was an abuse of her insurance policy

## Pulmonary Evaluation

- CT worse
- AFB smear +
- Pulmonologist makes presumptive dx of TB
- Started on RIPE 6/27/2013
- Over ensuing month, smears remain +
- Moxifloxacin started 8/8/2013







## Smear Conversion

- Two weeks after initiation of Moxifloxacin, AFB smears become negative
- Cultures growing MAC and MTB
- Difficulty obtaining sensitivities secondary to MAC overgrowth
- CXR worse
- Low serum drug levels (Rifampin and Ethambutol)
- Referred to LSH Outpatient Department on September 8th

## Seen in OPD not anxious for admission to LSH

- Should we treat MAC?
- Should we add additional drugs or await sensitivities?

## LSH

- ♦ 9/17/2013 sensitivities return:
  - ♦ Resistance to INH (at all levels), Rifampin, Ethambutol, Ethionamide
  - ♦ PZA pending
  - ♦ Sensitive to Cycloserine, Capreomycin and Ciprofloxacin
- ♦ How do we treat at this point?

## LSH Rx

- ♦ Rx Capreomycin 12 mg/kg IV (S)
- ♦ Continued Moxifloxacin (S initially)
- ♦ Continued PZA pending sensitivities
- ♦ Added Cycloserine 500 mg daily (S)
- ♦ Added Linezolid 600 mg daily (no testing)
- ♦ Patient feels much better on medications and tolerates meds well

## LSH Admission

- ◆ Hospitalized for 1 week to initiate IV therapy
- ◆ Then discharged to home
- ◆ But returned for daily IV infusion M-Friday for 10 days
- ◆ Now receiving IV infusion of Capreomycin at home

## TB Treatment

- ◆ 2 weeks into new TB treatment, CXR unchanged
- ◆ Additional information: initial sputum culture PZA resistant as well
- ◆ ? Rx changes

## Treatment course

- Started PASER (no testing for S yet)
- Isolate subsequently found to be Linezolid sensitive (send out)
- Capreomycin, Cycloserine, Linezolid, Moxifloxacin and PASER continued
- AFB culture growing from 9/9/2013
- Awaiting Moxifloxacin sensitivity from this later culture. Awaiting PASER sensitivity from initial culture
- Of 5 drugs, we know definitively she is sensitive to 3

## MAC/MTb

- Cultures consistently growing 2 organisms
- Presence of MAC on 9/10 culture makes sensitivities difficult. Colonies on initial culture hand picked for accuracy
- Cultures taken from shower head in apt and kitchen faucet
- Both grow MAC after 7 days!

## Do we treat MAC ?

- ♦ Change shower head and filter on faucet
- ♦ Is the MAC a pathogen?
- ♦ Do we eliminate exposure to MAC, or do we treat MAC?
- ♦ Should we do MAC sensitivity?

## New Problem

- ♦ Platelets fall to 110. Previously nl. Related to Linezolid?
- ♦ What to do?